American Cures Act
Summary
The American Cures Act authorizes and appropriates approximately $891B over 10 years for NIH and CDC biomedical research, with automatic CPI adjustments and exemptions from sequestration and PAYGO. This permanent funding commitment directly benefits life sciences tools companies ($TMO, $DHR) and clinical research organizations ($IQV, $ICLR, $ILMN) by guaranteeing a sustained increase in federal research spending.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The American Cures Act locks in ~$891B in mandatory-like biomedical research funding over 10 years, growing with CPI.
- 2.Life sciences tools companies ($TMO, $DHR) are the direct beneficiaries, as NIH grants fund equipment and consumables purchases.
- 3.CROs ($IQV, $ICLR) and sequencing leader ($ILMN) also benefit from expanded research pipelines and genomic studies.
- 4.The bill is early-stage and faces partisan hurdles, but its permanent funding structure makes it a long-term tailwind if enacted.
Market Implications
The American Cures Act provides a long-term demand signal for the life sciences tools and clinical research sectors. $TMO and $DHR, as market leaders in lab supplies, are positioned to capture a significant share of the incremental spending. $IQV and $ICLR benefit from expanded clinical trial activity. $ILMN gains from genomic research growth. Without real market data, specific price levels cannot be cited, but the structural revenue uplift is estimable. The bill's likelihood of passage in the 119th Congress is modest given divided control, but the bipartisan appeal of biomedical research funding could facilitate inclusion in must-pass legislation.
Full Analysis
-
What happened and current status: On May 12, 2026, Senator Durbin (D-IL) introduced S.4494, the American Cures Act, which was read twice and referred to the Senate Committee on Appropriations. The bill is in early legislative stage; four Democratic cosponsors have signed on. No companion bill has been introduced in the House.
-
The money trail: This bill is unusual because it both authorizes AND appropriates funding—it explicitly states 'there are hereby authorized to be appropriated, and appropriated' for NIH, CDC, DoD health program, and VA medical research. For NIH, FY2027 starts at $52.5B and escalates annually by CPI through FY2037 and beyond; CDC starts at $9.9B with similar escalations. Sum of specified NIH and CDC amounts for FY2027-2036 totals ~$891B. The bill exempts these funds from sequestration and both statutory and Senate PAYGO rules, making the spending mandatory-like. Note: The DoD health program and VA research amounts are also authorized but only partial figures are shown in the text.
-
Convergence: No related signals or procurements are provided in the enrichment data, so this bill is analyzed as a standalone legislative event.
-
Structural winners: The clear beneficiaries are companies supplying the infrastructure of biomedical research. Thermo Fisher ($TMO) and Danaher ($DHR) are the dominant players in lab equipment and consumables, with NIH-funded researchers as a core customer base. Clinical research organizations IQVIA ($IQV) and ICON ($ICLR) will see increased demand as NIH-funded basic research translates into more clinical trials. Illumina ($ILMN) is the leading genomic sequencing provider, and increased NIH genomics funding directly drives instrument and consumable sales. All these companies have high exposure to federal research funding streams.
-
Timeline and legislative steps: The bill is at the earliest stage—referred to committee. It must pass the Senate and House, then be signed by the President. Given the large fiscal commitment and partisan sponsorship (all Democrats), passage is uncertain in the current divided 119th Congress. The next key step is a committee hearing and markup in Appropriations. Progress will depend on budget negotiations and potential inclusion in omnibus spending bills.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Bill appropriates $52.5B for NIH in FY2027 with annual CPI-adjusted increases through FY2037 and beyond, funding research grants, equipment, and consumables.
Who must act
NIH-funded academic medical centers, universities, and research institutes
What happens
Increased demand for lab equipment, reagents, and consumables from NIH-funded researchers, estimated 3-5% incremental revenue growth in the life sciences tools market.
Stock impact
Thermo Fisher's Life Sciences Solutions and Fisher Scientific segments capture ~30% market share in lab supplies; incremental NIH funding directly boosts sales of mass specs, sequencers, chemicals, and plasticware. Estimated $500M-$1.5B additional annual revenue at peak funding levels.
What the bill does
Same NIH funding mechanism drives procurement of bioprocess equipment, diagnostics, and lab automation.
Who must act
NIH-funded research institutions
What happens
Higher spending on bioprocess chromatography, cell culture, and analytical instruments used in biomedical research.
Stock impact
Danaher's Life Sciences segment (Cytiva, Beckman Coulter, Sciex) sees increased instrument and consumable orders; estimated $300M-$1B in additional annual revenue.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
THE REGENTS OF THE UNIVERSITY OF COLORADO: $24.8M Department of Health and Human Services Grant
CARGO Act of 2025
LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
Gabriella Miller Kids First Research Act 2.0
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
RESTORING AMERICAN SALTWATER ANGLING AND RECREATION
This executive order directs federal agencies (primarily NOAA and the Department of Commerce) to shift fisheries management toward prioritizing recreational fishing over commercial interests by modernizing data collection, replacing outdated mail-in surveys with real-time mobile reporting, and allowing state-collected data to substitute for federal data when error rates are lower. It also mandates reviewing and potentially revising National Standards under the Magnuson-Stevens Act, rescinding regulations that restrict marine access, and launching pilot programs for iconic fisheries like Atlantic striped bass, with the goal of boosting the $1.2 trillion outdoor recreation sector.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →